There was no significant difference in OS (overall survival) or RFS between patients with RUNX1/RUNX1T1-rearranged AML or those with CBFB/MYH11-rearranged AML (Supplementary Fig. S4). This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.